We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+54.86%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$837M
(+116%)
Cap. Flow
+$592M
Cap. Flow
% of AUM
37.97%
Top 10 Holdings %
Top 10 Hldgs %
44.99%
Holding
85
New
33
Increased
20
Reduced
4
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$94.1M |
| 2 |
Baxter International
BAX
|
+$69.8M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$46.6M |
| 4 |
Arvinas
ARVN
|
+$45.7M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$41.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$49.1M |
| 2 |
Merck
MRK
|
+$37.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$25.5M |
| 4 |
Cardinal Health
CAH
|
+$24.2M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Sarepta Therapeutics
SRPT
$1.63B
| – | – |
-80,000
| Closed | -$7.83M |
|
77
Vertex Pharmaceuticals
VRTX
$124B
| – | – |
-34,000
| Closed | -$8.09M |
|
|
VIRX
78
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-123,143
| Closed | -$1.79M |
|
|
CTLT
79
DELISTED
CATALENT, INC.
CTLT
| – | – |
-411,000
| Closed | -$21.4M |
|
|
MRTX
80
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-295,000
| Closed | -$22.7M |
|
|
SGEN
81
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-117,700
| Closed | -$13.6M |
|
|
AERI
82
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-507,000
| Closed | -$6.84M |
|
|
XLRN
83
DELISTED
Acceleron Pharma
XLRN
| – | – |
-166,000
| Closed | -$14.9M |
|
|
AIMT
84
DELISTED
Aimmune Therapeutics
AIMT
| – | – |
-408,000
| Closed | -$5.88M |
|
|
AGN
85
DELISTED
Allergan plc
AGN
| – | – |
-40,000
| Closed | -$7.08M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q2 2020 Portfolio in Review
As of Q2 2020, Avidity Partners Management held 85 positions worth $1.56B, up 116% from $724M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Avidity Partners Management deployed $592M of net new capital in Q2 2020, opening 33 new positions and adding to 20 existing holdings. Its largest new stake was Baxter International: 800,900 shares worth $69M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.
On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $49.1M trimmed.
- Avidity Partners Management's largest Q2 2020 buy was Baxter International: 800,900 shares worth $69M.
- Avidity Partners Management added most to AbbVie in Q2 2020, an estimated $94.1M increase.
- Avidity Partners Management's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $49.1M.
- Avidity Partners Management fully exited Merck in Q2 2020, selling an estimated $37.9M.
- Avidity Partners Management's ten largest holdings make up 45% of its $1.56B portfolio in Q2 2020.
- Avidity Partners Management opened 33 new positions and closed 28 in Q2 2020.
- Avidity Partners Management's portfolio value rose 116% quarter-over-quarter to $1.56B.
Based on Avidity Partners Management's 13F filing for Q2 2020, filed 14 Aug 2020.